Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745420 | 1.00 | LMNA (0.41) | LMNAMAPK1POLBSRCCYP2D6 | |
| Butane SCHEMBL23346235 | 0.91 | POLB (0.45) | LMNAMAPK1POLBKMT2ATSHR | |
| SCHEMBL5745417 | 0.84 | LMNA (0.43) | LMNAMAPK1POLBSRCCYP2D6 | |
| SCHEMBL64259 | 0.84 | LMNA (0.43) | LMNAMAPK1POLBSRCCYP2D6 | |
| SCHEMBL8173543 | 0.81 | SRC (0.37) | LMNAMAPK1POLBSRCCYP2D6 | |
| SCHEMBL767298 | 0.80 | ESR1 (0.40) | LMNAMAPK1POLBSRCCYP2D6 | |
| SCHEMBL8173087 | 0.79 | IDO1 (0.38) | LMNACES2CES1ALDH1A1 | |
| SCHEMBL9634198 | 0.79 | LMNA (0.39) | LMNAMAPK1POLBSRCCYP2D6 | |
| SCHEMBL28363774 | 0.79 | TSHR (0.40) | LMNAMAPK1CYP2D6TSHRALDH1A1 | |
| SCHEMBL2795973 | 0.77 | TDP1 (0.38) | LMNAMAPK1POLBSRCCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4728075-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOE | Leal Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4677090-A2 | COMPOSITIONS AND METHODS FOR MODULATING C3 | Leal Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4677091-A2 | COMPOSITIONS AND METHODS FOR MODULATING GRIN2A | Leal Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4677089-A2 | COMPOSITIONS AND METHODS FOR MODULATING SPTLC1 | Leal Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4677088-A2 | COMPOSITIONS AND METHODS FOR MODULATING GLS1 | Leal Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4633669-A2 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250281590-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED ESCHERICHIA COLI SACCHARIDES AND USES THEREOF | PFIZER (US) | 2025-09-11 | — | — | US | disclosed |
| US-12404507-B2 | Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases | THE GENERAL HOSPITAL CORPORATION | 2025-09-02 | — | — | US | disclosed |
| EP-4569116-A2 | IDENTIFICATION OF ALLELE-SPECIFIC TARGET SEQUENCES FOR C9ORF72 | The University of Massachusetts (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4087931-B1 | NOVEL TLR9 AGONISTS | SBI BIOTECH CO LTD (JP) | 2024-12-25 | — | — | EP | disclosed |
| WO-2004005476-A2 | NUCLEIC ACID COMPOSITIONS FOR STIMULATING IMMUNE RESPONSES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-6472521-B1 | Oligonucleotides for the inhibition of human eg5 expression | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
| US-20010021772-A1 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-13 | — | — | US | disclosed |
| EP-1102842-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | Aventis Pharma Deutschland GmbH (DE) | 2001-05-30 | — | — | EP | disclosed |
| EP-1100894-A2 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | Aventis Pharma Deutschland GmbH (DE) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000008140-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-02-17 | — | — | WO | disclosed |
| WO-2000008141-A2 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-02-17 | — | — | WO | disclosed |
| EP-0979869-A1 | Short oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-16 | — | — | EP | disclosed |
| EP-0978561-A1 | Antisense oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-09 | — | — | EP | disclosed |
| US-5719257-A | OBTAINED BY ANIONIC POLYMERIZATION OF DERIVATIVES OF 2,2,6,6-TETRAMETHYL-4-/2,3-EPOXYPROPOXY/PIPERIDINE | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281590-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED ESCHERICHIA COLI SACCHARIDES AND USES THEREOF | C5AR1, C3AR1, C5 | LMNA 3913/4885MAPK1 3407/4885POLB 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.